GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...

Pfizer (NYSE:PFE) has reportedly succeeded in getting a U.K. court to invalidate two of GSK’s (NYSE:GSK) patents for its RSV ...

Millions of people who bought DNA tests from genetic testing service 23andme have been urged to delete their personal data ...

Pfizer on Monday won a bid in a London court to invalidate two of GSK's patents relating to a respiratory syncytial virus ...

DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...

ViiV Healthcare to triple annual supply of long-acting HIV PrEP for low- and middle-income countries ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.

The life sciences developer acquired the site as part of a master lease agreement with seller MIT that expires in 2099.

EU regulators are considering withdrawing market authorizations for two hair loss and enlarged prostate treatments over ...

GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, ...

"I've watched and been a part of Illumina growing from a startup to one of the most important and innovative companies in the ...

DNA submitted by users to the genealogy company 23andMe will remain private for now, with CEO Anne Wojcicki saying she no ...